Skip to main content
NewslettersWatchlist

Bioasis Technologies Inc(BTI-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.005
Day High0.005
Open:0.005
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Bioasis Technologies: Top 10 Undervalued Biotechnology Industry Stocks (BTI)
AI-generated - The Globe and Mail
Bioasis Technologies: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (BTI)
AI-generated - The Globe and Mail
Bioasis Technologies: Top 10 Undervalued Biotechnology Industry Stocks (BTI)
AI-generated - The Globe and Mail
Bioasis Technologies: Top 10 Undervalued Biotechnology Industry Stocks (BTI)
AI-generated - The Globe and Mail
Bioasis Technologies: Top 10 Undervalued Biotechnology Industry Stocks (BTI)
AI-generated - The Globe and Mail
Bioasis Technologies: Bottom 25 Performing Stocks Year-to-Date on TSX-V (BTI)
AI-generated - The Globe and Mail
Bioasis Technologies: Bottom 25 Performing Stocks Year-to-Date on TSX-V (BTI)
GlobeNewswire
Bioasis Provides Corporate Update and Announces Suspension of Operations
The Globe and Mail
Bioasis Technologies: Bottom 25 Performing Stocks Year-to-Date on TSX-V (BTI)
The Globe and Mail
Bioasis Technologies: Top 25 Undervalued Dividend Stocks on TSX-V (BTI)
The Globe and Mail
Bioasis Technologies: Top 10 Undervalued Biotechnology Industry Stocks (BTI)
The Globe and Mail
Bioasis Technologies: Top 25 Undervalued TSX Venture Exchange Stocks (BTI)
The Globe and Mail
Bioasis Technologies: Bottom 25 Performing Stocks Year-to-Date on TSX-V (BTI)
Globe Newswire
Bioasis Technologies Inc. Announces Stock Option Grants
Globe Newswire
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
Globe Newswire
Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets
Globe Newswire
Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A
Globe Newswire
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
Globe Newswire
Bioasis Enters Into Research Collaboration With Janssen
Globe Newswire
Bioasis to Attend and Present at Upcoming Industry Conference
Globe Newswire
Bioasis Announces $200,000 Non-Brokered Private Placement
Globe Newswire
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2021
Globe Newswire
Bioasis Announces Annual General Meeting Results
Globe Newswire
Bioasis to Attend and Present at Upcoming Industry Conferences
Globe Newswire
Bioasis Announces Annual General Meeting Details
Globe Newswire
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2021
Globe NewsWire
Bioasis to Attend Upcoming Industry Conferences
Globe NewsWire
Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor
Globe NewsWire
Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xBยณโ„ข Fusion Protein Comprising Iduronate-2-sulfatase
Globe NewsWire
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
Globe NewsWire
Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager
Globe NewsWire
Bioasis Announces Positive Results From an Efficacy Study of xB3โ„ข-IL-1RA in a Model of Multiple Sclerosis

Profile

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.